EUVIMEDEUVIMED entdecken
Querschnittstudie

Mucormycosis in Post Covid Patients Attending a Tertiary Care Hospital in West Bengal - A Cross-Sectional Study

Reena Ray Ghosh, Suranjan Pal, Kumkum Bhattacharyya, Tannistha Ray, Soumya Bhattacharya, Suvendu Pradhan

International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)

DOI: 10.25258/ijcpr.18.5.97 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von Reena Ray Ghosh und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID-19 pandemic has been accompanied by a surge of secondary fungal infections, particularly mucormycosis, in India. Post-COVID mucormycosis has emerged as a severe opportunistic infection, largely affecting patients with uncontrolled diabetes mellitus and those treated with corticosteroids. We undertook the study to determine the occurrence of COVID associated mucormycosis, establish the association of risk factor(s), identify and characterize the agents of mucormycosis.

Methods

This prospective observational and cross-sectional descriptive study was conducted at a tertiary care hospital in West Bengal, India. A total of 107 COVID-19 patients with clinical suspicion of mucormycosis were included. Microbiological diagnosis relied on KOH wet mount examination, fungal culture, histopathological staining, and molecular methods like RT-PCR for confirmation.

Results

The study revealed a high mortality rate of 21.5% among post-COVID mucormycosis patients. Uncontrolled diabetes with diabetic ketoacidosis, chronic kidney disease, chronic liver disease, and shorter interval between COVID recovery and mucormycosis onset were significant predictors of mortality. Rhizomucor pusillus was the predominant fungal isolate. Combined surgical and medical therapy, including aggressive debridement and antifungal therapy, was the mainstay of treatment.

Conclusion

Post-COVID mucormycosis was a major public health concern in India, with high mortality rates despite early intervention. Strict glycemic control, early diagnosis, and comprehensive management of comorbidities are essential to improve survival outcomes. Our study highlights the need for rational corticosteroid use, diabetes control, and multidisciplinary management to prevent future outbreaks. Future research should focus on understanding host-pathogen interactions, resistance patterns, and developing rapid diagnostic assays to enable timely intervention in high-risk patients.

Zitieren

APA

Ghosh, R. R., Pal, S., Bhattacharyya, K., Ray, T., Bhattacharya, S., & Pradhan, S. (2026). Mucormycosis in Post Covid Patients Attending a Tertiary Care Hospital in West Bengal - A Cross-Sectional Study. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.97

Vancouver

Ghosh RR, Pal S, Bhattacharyya K, Ray T, Bhattacharya S, Pradhan S. Mucormycosis in Post Covid Patients Attending a Tertiary Care Hospital in West Bengal - A Cross-Sectional Study. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.97

BibTeX
@article{Ghosh2026,
  author = {Ghosh, Reena Ray and Pal, Suranjan and Bhattacharyya, Kumkum and Ray, Tannistha and Bhattacharya, Soumya and Pradhan, Suvendu},
  title = {Mucormycosis in Post Covid Patients Attending a Tertiary Care Hospital in West Bengal - A Cross-Sectional Study},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {05},
  doi = {10.25258/ijcpr.18.5.97}
}
Kostenlos starten →